Furthermore, wildtype Akt1, but not the S473A mutant, appeared to be associated with 3 OGT following glucosamine treatment. Together, these observations suggest that Akt1 Ser473 may undergo both phosphorylation and O-GlcNAc modification, and the balance between these may regulate murine β-pancreatic cell fate.
Introduction
In contrast to N-linked glycosylation of membrane or secreted proteins, attachment of the monosaccharide of O-linked N-acetylglucosamine (O-GlcNAc) to Ser and/or Thr residues occurs mainly on nuclear and cytosolic proteins [1, 2] . The O-GlcNAc modification is dynamically catalyzed by O-GlcNAc transferase (OGT) [3] and removal of O-GlcNAc is achieved by O-GlcNAc-selective N-acetyl-β-Dglucosaminidase (O-GlcNAcase) [4] . O-GlcNAc modification of Ser/Thr residue(s) on a specific protein can modulate the activity of that molecule to the extent of ultimately regulating cell function or behavior [2, 4] .
Many studies have indicated that activation of hexosamine biosynthesis pathway (HBP), which serves as a nutrient sensor, can lead to abnormalities in protein OGlcNAc modification that may be associated with insulin resistance and diabetic complications [5] .
When physiological changes in extracellular glucose concentrations are detected by β-pancreatic cells that are uniquely enriched with OGT [6] , glucose is converted to glucose-6-phosphate and then to fructose-6-phosphate [7] .
The rate-limiting conversion of fructose-6-phosphate to glucosamine-6-phosphate is mediated by L-glutamine:fructose-6-phosphate amidotransferase (GFAT) [8] .
Glucosamine-6-phosphate can subsequently be converted to UDP-N-acetylglucosamine (UDP-GlcNAc), the requisite substrate for O-GlcNAc modification of many different proteins [9] . Therefore, an enhanced glucose flux through the HBP can increase O-
GlcNAc-modification of proteins in response to nutrient levels. Intracellular accumulation of O-GlcNAc-modified proteins can also be achieved by inhibition of O-
GlcNAcase [4] .
Patients with type II diabetes are characterized by reduced secretion of insulin by β-pancreatic cells in response to hyperglycemia combined with impaired ability of skeletal muscle, fat and liver cells to respond to insulin [10] . The failure of β-cells to compensate for the insulin demand results from reduced β-cell mass through their necrosis and apoptosis [11] . Thus, a loss in pancreatic β-cell mass may intensify the functional defects, and cause further impairment of the aberrant insulin secretion observed in inefficiently controlled diabetes [12] . O-GlcNAc modification of certain proteins is known to be associated with β-cell apoptosis in hyperglycemic conditions [11] .
The anti-apoptotic protein Akt1 is activated by phosphorylation [13] ; specifically, phosphorylation at Thr308 and Ser473 is required for full Akt1 activity [14] . Akt1 in turn phosphorylates diverse downstream molecules including caspase 3, Bad, forkhead transcription factor (FOXO family), and GSK3β, inhibiting their pro-apoptotic activities and promoting cell survival [14] . Interestingly, the phosphorylation level of Ser473 is modulated by hyperglycemic conditions [12] , and Akt1 may also be modified
with O-GlcNAc [15] . However, it is currently not clear which Ser/Thr residue(s) of Akt1 are O-GlcNAc-modified and how the O-GlcNAc modification is related to its phosphorylation. Results of this study indicate that Akt1 Ser473 may be modified
with O-GlcNAc, and that O-GlcNAc modification and phosphorylation of Ser473 are reciprocally regulated by hyperglycemic treatment in murine β-pancreatic cells. 
Materials and Methods

MALDI-TOF/TOF:
Spots on silver-stained gels corresponding to Akt1 were excised, destained by reduction using 30 mM potassium ferricyanide/100 mM sodium thiosulfate, and washed with distilled water for MALDI-TOF/TOF analysis as described previously [19] . Briefly, gel pieces were incubated with 0. Treatment with glucosamine also induced cell death in mouse βTC-6 pancreatic cells (Fig. 1D ). These observations confirm that glucosamine treatment of murine β-pancreatic cells caused caspase-dependent apoptosis.
Hyperglycemic conditions increased O-GlcNAc modification and concomitantly decreased Ser473 phosphorylation of Akt1.
When murine β-pancreatic cells were treated with glucosamine (7. (Fig. 2C) . Furthermore, phosphorylation of GSK3β, a substrate of Akt1, was reduced following glucosamine treatment, indicating that glucosamine treatment decreased Akt1 activity (Fig. 2B ).
These observations indicate that Akt1 Ser473 phosphorylation, and thus activity, might be mutually exclusive with O-GlcNAc modification, although it is not clear whether the modified residues are the same. O-GlcNAc modifications were decreased, whereas pS 473 Akt1 levels were increased ( Fig. 3A and B) . On the other hand, when removal of O-GlcNAc was blocked by
OGT or O-GlcNAcase
PUGNAc treatment, the basal pS 473 Akt1 level was slightly reduced, whereas glucosamine-mediated pS 473 Akt1 levels were not observed regardless of whether PUGNAc was treated or not (Fig. 3C) . Interestingly, pT 308 Akt1 levels were not significantly changed by PUGNAc treatment, although they were slightly reduced by treatment with 7.5 mM GlcN (Fig. 3C) . In the absence of glucosamine, exogenous expression of Akt1 WT, but not S473A mutant, increased levels of pS 473 Akt1 (Fig. 6A, lanes 1 to 3) . However, pS 473 Akt1
was not detected following glucosamine treatment, regardless of whether Akt1 WT or S473A mutant was expressed (Fig. 6A, lanes 4 to 6) . O-GlcNAc modification of Akt1 occurred when the cells overexpressed Akt1 WT, but not S473A mutant protein, and was further increased when the cells were treated with glucosamine, compared with the untreated control (Fig. 6A, bottom) . Cell viability assays showed that viability was (Fig. 6C, lanes 1 and 3) . However, when the cells were transfected with S473A mutant Akt1, O-GlcNAc modifications were abolished in both control and ncOGT-overexpressing cells (Fig. 6C, lanes 2 and 4) , further indicating that Ser473 is targeted by OGT. Reciprocally, pS 473 Akt1 levels were partially reduced by transfection with the S473A mutant, presumably due to incomplete transfection efficiency, and pS 473 Akt1 levels were lower in the ncOGT-overexpressing cells than in control cells (Fig. 6C) OGT associated with Akt1 WT, but not S473A mutant, following glucosamine treatment.
We next examined the effect of hyperglycemic conditions on the localization of OGT and Akt1 via a coimmunoprecipitation approach. Immunoprecipitates using anti-HA antibody from cells transfected with either WT Akt1 or S473A mutant Akt1 tagged with (HA) 3 were immunoblotted for OGT. When treated with glucosamine, Akt1 WT co-immunoprecipitated OGT (presumably ncOGT of 116 kD), whereas S473A mutant did not (Fig. 7) . This observation suggests that modification of Akt1
Ser473 with O-GlcNAc could be mediated by physical association between Akt1 and OGT, following a hyperglycemic treatment of INS-1 cells.
Discussion
Observations from this study indicated that Ser473 of Akt1 was modified with OGlcNAc when murine β-pancreatic cells were treated with glucosamine, a direct precursor of the downstream product of the hexosamine biosynthesis pathway (HBP).
We found that a tryptic-digested peptide of Akt1 (amino acids 466 to 480 including (Table  1) .
Furthermore, the calculated potential for Ser473 to be O-GlcNAc-modified is higher than that for Thr479 (Table 1) , and we observed that a T479A mutant of Akt1, but not a Since O-GlcNAc modification occurs at Ser/Thr residues, it is likely that O-GlcNAc modification and phosphorylation are reciprocally regulated under certain circumstances, leading to regulation of the protein's activity and stability [21, 22] . Dynamic regulation of O-GlcNAc modification turnover in response to extracellular fluctuations in glucose levels may allow modulation of the signaling activities of certain intracellular proteins in β-pancreatic cells [4, 23, 24] . In particular, in diabetes mellitus, increased O-GlcNAc modification of many proteins under extracellular hyperglycemic conditions appears to be correlated with β-pancreatic cell death [11, 25] .
Glucosamine treatment of human islets of Langerhans and RIN rat β-pancreatic cells increases apoptosis due to serum-deprivation through impaired activation of the insulin receptor (IR)/IR substrate (IRS)/PI3-K/Akt survival pathway [10] . However, in this previous study, glucosamine treatment of β-pancreatic cells appeared to cause OGlcNAc modification of IR/IRS, upstream of PI3-K/Akt [10] . Although the O- Cell Viability
